Browse the evidence

Rural areas had a higher incidence of CVD (5.41 per 1000 person-years) and a higher mortality rate (10.27 per 1000 person-years) compared to urban areas.

Targeted interventions in rural areas may be necessary to reduce CVD incidence and mortality.

Four metabolic parameters predict weight gain in Pima Indians: low relative resting metabolic rate (RMR), low level of spontaneous physical activity (SPA), high 24 h respiratory quotient (RQ), and high insulin sensitivity (IS).

Practitioners should consider these metabolic parameters when assessing weight gain risk.

After gaining weight, the original deviation from predicted metabolic values tends to diminish, indicating a decreasing physiological drive for further weight gain.

This suggests that metabolic adaptations may limit further weight gain after initial increases.

Cardiovascular disease (CVD), cancer, and respiratory diseases account for over two-thirds of deaths in South America.

Health interventions should focus on CVD, cancer, and respiratory diseases to reduce mortality.

Many observational studies have shown an association between variation in body weight and increased morbidity and mortality.

Weight variation may be linked to health risks, warranting monitoring.

The workshop emphasized the optimization of interventions and the effectiveness and implementation of trials.

Practitioners should consider these emphasized areas to improve behavioral intervention effectiveness.

Greater hypothalamic inflammation and gliosis may predict adiposity gain and worsening insulin sensitivity.

Monitoring hypothalamic inflammation could be important for predicting weight gain and metabolic decline.

Individuals participating in SNAP exhibited higher total and cardiovascular disease mortality than both SNAP-eligible nonparticipants and SNAP-ineligible individuals.

Public health efforts should prioritize understanding and addressing the health outcomes of SNAP participants.

Participants in SNAP have higher diabetes mortality across races/ethnicities.

Health interventions should consider the increased diabetes mortality risk among SNAP participants.

GLP-1 receptor agonists exert tissue-protective effects across multiple organs (pancreas, heart, liver, adipose, muscle, kidney, brain) primarily by driving mitochondrial remodeling, including improved biogenesis, quality control, and reduced oxidative stress.

GLP-1 medications (like semaglutide or liraglutide) do more than just help you lose weight; they actively improve the energy-producing centers (mitochondria) in your heart, liver, and other organs. This cellular repair helps protect these organs from damage, offering benefits that go beyond simple calorie reduction.

In pancreatic beta cells, GLP-1 receptor agonists directly protect against apoptosis and improve insulin secretion by enhancing mitochondrial ATP production, reducing oxidative stress, and promoting autophagy.

For people with Type 2 Diabetes, GLP-1 drugs help preserve the insulin-producing cells in the pancreas by keeping their energy factories (mitochondria) healthy and reducing cellular stress. This helps maintain the body's natural ability to produce insulin.

Calorie restriction may involve significant alterations in energy metabolism, oxidative damage, and insulin sensitivity.

Understanding these mechanisms may help in developing interventions for aging and chronic diseases.

Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice.

Practitioners should stay informed about new pharmacological options for obesity management.

Body mass index (BMI) and waist circumference increased in both sexes over five years.

Practitioners should be aware of the increasing adiposity trends in this population.

Women moved to higher BMI categories and more were diagnosed with central obesity over five years.

Interventions should target women to address rising obesity rates.

Socio-economic status (SES), physical activity, energy, and fat intake correlated positively with adiposity markers in women.

Understanding these correlations can help tailor interventions for women.

No significant association was found between the multidimensional macronutrient quality index (MQI) and all-cause mortality.

Practitioners should note that overall macronutrient quality, as measured by the MQI, does not appear to influence all-cause mortality risk.

The hazard ratio for the highest vs. the lowest quartile of the MQI was 0.79, indicating no significant difference in mortality risk.

The lack of significant difference in mortality risk suggests that overall macronutrient quality may not be a critical factor for longevity.

Incretin therapies could ameliorate fatty liver disease, chronic inflammation, sleep apnea, and possibly degenerative bone disorders and cognitive decline.

Incretin therapies may be considered for patients with these co-morbidities, pending further research.

GLP-1 receptor agonists exert direct antihypertensive effects independent of weight loss by modulating the sympathetic nervous system, improving endothelial function, enhancing renal sodium excretion, and suppressing the renin-angiotensin-aldosterone system.

Even without losing weight, GLP-1 medications help lower blood pressure by directly relaxing blood vessels, helping your kidneys excrete more sodium, and calming the nervous system signals that raise blood pressure. They also reduce the activity of hormones that constrict blood vessels.

A nomogram was established and validated for predicting the risk of type 2 diabetes in obese patients with non-alcoholic fatty liver disease.

Clinicians can use this nomogram for risk stratification in obese NAFLD patients.

The nomogram was constructed using five independent predictors selected from 17 variables.

Understanding the predictors can help in tailoring prevention strategies.

The model demonstrated good predictive power as indicated by the AUC values at different time points.

The nomogram can be reliably used in clinical settings for risk assessment.

There are predisposing risk factors for type 2 diabetes that can be reviewed.

Understanding risk factors can help in tailoring prevention strategies.